ClinicalTrials.gg
Not yet recruitingNCT07720921LUXUS0701Updated Nov 16, 2026

Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )

A Phase 2 interventional study of Neoadjuvant radiotherapy and ADC + PD1 monoclonal antibody in Urothelial Carcinoma of the Renal Pelvis and Ureter and Neoadjuvant Therapy, sponsored by Peking University First Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Peking University First Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Eligibility revisedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, single-arm, single-cohort, prospective clinical study evaluating neoadjuvant antibody-drug conjugate therapy combined with immunotherapy and sequential radiotherapy followed by radical surgery in patients with high-risk upper tract urothelial carcinoma (UTUC). Eligible patients will receive neoadjuvant disitamab vedotin (RC48) plus toripalimab, followed by response-guided neoadjuvant radiotherapy and radical nephroureterectomy with bladder cuff excision. The study will assess the safety, feasibility, and preliminary antitumor activity of this multimodal neoadjuvant strategy, with pathological complete response rate as the primary endpoint.

Read the detailed description

High-risk UTUC is associated with a substantial risk of recurrence and metastasis after radical surgery. Many patients are unable to tolerate cisplatin-based perioperative chemotherapy because of impaired renal function or treatment-related toxicity. Radiotherapy may improve local control, and low-dose radiation may also modulate the tumor immune microenvironment. Combining an antibody-drug conjugate, immune checkpoint blockade, and sequential radiotherapy before surgery may provide systemic tumor control, enhance local tumor response, and improve pathological downstaging.

This study will enroll patients with resectable, non-metastatic, T2-T4N0-1M0 UTUC at Peking University First Hospital. Patients will undergo baseline imaging, pathological confirmation, biomarker evaluation, and collection of blood, urine, and tumor specimens. A safety run-in phase of 6 patients will be used to evaluate early safety and dose-limiting toxicities during the first treatment cycle, with special attention to days 7-14. If the safety threshold is met, an additional 14 patients will be enrolled. Interim efficacy assessment will be performed before the penultimate systemic treatment cycle to guide subsequent radiotherapy and surgical planning. Patients will then undergo radical surgery when clinically appropriate and will be followed for recurrence, metastasis, survival, safety, and exploratory molecular endpoints.

02

Conditions studied

  • Urothelial Carcinoma of the Renal Pelvis and Ureter
  • Neoadjuvant Therapy

Keywords

  • UTUC
  • neoadjuvant radiotherapy
  • neoadjuvant immunotherapy
  • neoadjuvant Antibody-Drug Conjugate
  • prospective cohort
  • disitamab vedotin
03

In context

Lead sponsor

Peking University First Hospital is the lead sponsor of 393 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age and Gender: Age ≥18 years, male or female.
  • Disease Status: Imaging highly suggests urothelial carcinoma (UC) and the lesion is evaluated as resectable.
  • Clinical Staging: Imaging evaluation indicates clinical stage cT2-4 N0-1M0 (including high-risk features such as muscle-invasive disease, high-grade tumor, multifocal disease, tumor diameter ≥2 cm, hydronephrosis, or regional lymph node involvement).
  • Pathological Diagnosis: confirmed diagnosis of UC by /puncture. The urothelial carcinoma component must be >50% (may include special differentiation types such as squamous, adenoid, or sarcomatoid differentiation comprising no more than 50%).
  • Molecular Biomarkers: expression by immunohistochemistry (IHC) of 1+ to 3+; expression is not restricted.
  • Prior Therapy: No prior receipt of other drugs or radiotherapy (corresponding to the absence of systemic chemotherapy and pelvic/abdominal radiotherapy history).
  • Performance Status: performance status score of 0-1.
  • Compliance and Consent: Willingness to undergo radical surgical treatment and perioperative adjuvant treatment; good compliance; and ability to cooperate with the treatment and follow-up plan specified by the clinician. Postoperative of at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Distant or other malignant neoplastic diseases combined with other malignant neoplasms in the same period had been detected at the time of surgery, or the present was a progression after palliative resection of previous epithelial carcinoma of the urothelium;
  • History of pelvic and abdominal radiotherapy; history of inflammatory bowel disease; history of systemic chemotherapy;
  • Pregnant women or breastfeeding women; or women of who are not using reliable ;
  • The presence of active infections in those with pre-existing or coexisting haemorrhagic disorders
  • cardiac disease (e.g., hypertension controlled with medications, unstable angina, (NYHA) class ≥II congestive heart failure, unstable symptomatic arrhythmias, or class ≥II peripheral vascular disease);
  • Psychological, familial, and social factors leading to lack of .
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant ADC, immunotherapy and radiotherapy + radical surgery

    Participants in this single cohort will receive neoadjuvant disitamab vedotin (RC48) plus toripalimab, followed by response-guided targeted-volume radiotherapy and radical nephroureterectomy with bladder cuff excision. Surgery is planned approximately 2-4 weeks after completion of the last neoadjuvant treatment, if the patient's clinical condition permits.

    Radiation: Neoadjuvant radiotherapy · Drug: ADC + PD1 monoclonal antibody

Interventions

  • RadiationNeoadjuvant radiotherapy

    Patients with a clear pathological diagnosis of high-risk UTUC were treated with a short course of 5 days of naSBRT: radiotherapy irradiation was directed to the primary lesion on the affected side and to the lymphatic drainage area, with a dose of 25 Gy (5 Gy\*5 days).The safety of the neoadjuvant radiotherapy dose and regimen can be evaluated by metrological ramping in the initial 5 patients, with subsequent patients following the optimal dose from ramping.

  • DrugADC + PD1 monoclonal antibody

    Participants will receive disitamab vedotin (RC48) 2.0 mg/kg intravenously every 2 weeks, on day 1 of each 14-day cycle, for up to 6 cycles, with a maximum safe dose of 120 mg. Participants will also receive toripalimab 3.0 mg/kg intravenously every 2 weeks, on day 1 of each 14-day cycle, for up to 6 cycles. A safety run-in phase will evaluate dose-limiting toxicities. If ≥2 of the first 6 patients experience DLT, the ADC schedule will be adjusted from every 2 weeks for 6 cycles to every 3 weeks for 4 cycles, with continued safety and efficacy monitoring.

06

What researchers measure

Primary outcomes

  1. Pathological complete response rate

    Proportion of participants with no residual viable tumor in the surgical specimen, as assessed by pathological evaluation.

    Time frame: At radical surgery

Secondary outcomes

  1. Objective response rate

    Rate of participants achieving complete response or partial response based on imaging assessment using RECIST or protocol-defined criteria.

    Time frame: At 2 months after initiation of treatment

  2. Treatment-related adverse events

    Incidence and severity of treatment-related adverse events and serious adverse events, graded according to CTCAE.

    Time frame: through study completion, an average of 1 year"

  3. Disease-free survival

    Time from radical surgery to disease recurrence, progression, or death from any cause

    Time frame: Up to 1 year and 3 years after surgery

  4. Local recurrence-free survival

    Time from radical surgery to local recurrence, including recurrence in the operative bed or regional retroperitoneal lymph nodes.

    Time frame: Up to 3 years after surgery.

  5. Metastasis-free survival

    Time from radical surgery to distant metastasis.

    Time frame: Up to 3 years after surgery.

  6. Overall survival

    Description

    Time frame: Up to 3 years after surgery.

Other outcomes

  1. Changes in plasma circulating tumor DNA (ctDNA) levels

    Changes in plasma circulating tumor DNA and association with radiographic response, pathological response, recurrence, and survival.Plasma ctDNA will be assessed using a tumor-informed personalized next-generation sequencing (NGS) assay.

    Time frame: Baseline, 2 months after the first dose, and within 2 weeks after surgery

  2. Urinary tumor DNA dynamics

    Changes in urinary tumor DNA and association with tumor burden, molecular residual disease, and clinical outcomes

    Time frame: Baseline, interim assessment during neoadjuvant treatment,post-radiotherapy assessment.

07

Study locations

1 site
  • Departmeng of Urology, Peking University First Hospita
    Beijing, Beijing Municipality, China
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jul 22, 2026
StartEst.
Nov 1, 2026was Aug 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Nov 1, 2026
Oct 28, 2026
Eligibility
4 inclusion criteria edited, 4 added, 3 removed
What changed in the criteria
Inclusion criteria
  • EditedAge and Gender: Age ≥18 years, male or female.
  • RemovedImaging evaluation before treatment excludes distant organ metastasis or other concurrent malignancy and suggests resectable high-risk UTUC.
  • RemovedCompleted pathological biopsy with a clear pathological diagnosis : including puncture biopsy, ureteroscopy and urine cytology, at least one of which is clearly diagnosed as uroepithelial carcinoma, which may include no more than 50% or more proportion of squamous, adenoid, sarcomatoid differentiation and other special differentiation types;
  • AddedDisease Status: Imaging highly suggests urothelial carcinoma (UC) and the lesion is evaluated as resectable.
  • EditedHighClinical Staging: Imaging evaluation indicates clinical stage cT2-4 N0-1M0 (including high-risk features, including such as muscle-invasive disease, high-grade tumor, multifocal disease, tumor diameter ≥2 cm, hydronephrosis, or regional lymph node involvement).
  • AddedPathological Diagnosis: Pathologically confirmed diagnosis of UC by biopsy/puncture. The urothelial carcinoma component must be >50% (may include special differentiation types such as squamous, adenoid, or sarcomatoid differentiation comprising no more than 50%).
  • EditedMolecular Biomarkers: HER2 expression by immunohistochemistry (IHC) of 1+ to 3+; PD-L1 expression is not restricted.
  • AddedPrior Therapy: No prior receipt of other neoadjuvant drugs or radiotherapy (corresponding to the absence of systemic chemotherapy and pelvic/abdominal radiotherapy history).
  • AddedPerformance Status: ECOG performance status score of 0-1.
  • EditedHave the willingnessCompliance and Consent: Willingness to undergo radical surgical treatment and perioperative adjuvant treatment, have; good compliance,; and be ableability to co-operatecooperate with the treatment and follow-up plan specified by the clinician;. Postoperative life expectancy of at least 6 months.
  • RemovedPostoperative life expectancy of at least 6 months; ECOG score ≤ 2.
Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    Eligibility 4 inclusion criteria edited, 4 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • EditedAge and Gender: Age ≥18 years, male or female.
    • RemovedImaging evaluation before treatment excludes distant organ metastasis or other concurrent malignancy and suggests resectable high-risk UTUC.
    • RemovedCompleted pathological biopsy with a clear pathological diagnosis : including puncture biopsy, ureteroscopy and urine cytology, at least one of which is clearly diagnosed as uroepithelial carcinoma, which may include no more than 50% or more proportion of squamous, adenoid, sarcomatoid differentiation and other special differentiation types;
    • AddedDisease Status: Imaging highly suggests urothelial carcinoma (UC) and the lesion is evaluated as resectable.
    • EditedHighClinical Staging: Imaging evaluation indicates clinical stage cT2-4 N0-1M0 (including high-risk features, including such as muscle-invasive disease, high-grade tumor, multifocal disease, tumor diameter ≥2 cm, hydronephrosis, or regional lymph node involvement).
    • AddedPathological Diagnosis: Pathologically confirmed diagnosis of UC by biopsy/puncture. The urothelial carcinoma component must be >50% (may include special differentiation types such as squamous, adenoid, or sarcomatoid differentiation comprising no more than 50%).
    • EditedMolecular Biomarkers: HER2 expression by immunohistochemistry (IHC) of 1+ to 3+; PD-L1 expression is not restricted.
    • AddedPrior Therapy: No prior receipt of other neoadjuvant drugs or radiotherapy (corresponding to the absence of systemic chemotherapy and pelvic/abdominal radiotherapy history).
    • AddedPerformance Status: ECOG performance status score of 0-1.
    • EditedHave the willingnessCompliance and Consent: Willingness to undergo radical surgical treatment and perioperative adjuvant treatment, have; good compliance,; and be ableability to co-operatecooperate with the treatment and follow-up plan specified by the clinician;. Postoperative life expectancy of at least 6 months.
    • RemovedPostoperative life expectancy of at least 6 months; ECOG score ≤ 2.
    + 1 other change: description
  2. Oct 28, 2026
    Start date Aug 1, 2026→Nov 1, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07720921
Responsible party
Xuesong Li (Director of the Department of Urology, Peking University First Hospital) — Principal investigator
First posted
Jul 22, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

ZUO WEI, Dr
Contact
vivian19980814@126.com
+8618811650832

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion